Literature DB >> 18317540

Rapid oral desensitisation procedure in clopidogrel hypersensitivity.

B Oppedijk1, D A M Odekerken, J J van der Wildt, C F Melissant.   

Abstract

We describe a patient who developed generalised pruritus with oedema and rash two weeks after she had started taking clopidogrel following coronary stent implantation. In the absence of other likely causative agents, clopidogrel hypersensitivity was probable. She was treated with a rapid oral desensitisation procedure, after which a daily dose of 75 mg clopidogrel was well tolerated. No major adverse events occurred during a follow-up period of eight months. Oral desensitisation in clopidogrel hypersensitivity seems to be a safe method to reduce the risk of coronary stent thrombosis. (Neth Heart J 2008;16:21-3.).

Entities:  

Keywords:  clopidogrel hypersensitivity; desensitisation; stent; thrombosis

Year:  2008        PMID: 18317540      PMCID: PMC2246315          DOI: 10.1007/BF03086112

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  15 in total

1.  Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting.

Authors:  G Y Szto; T J Linnemeier; M W Ball
Journal:  Am J Cardiol       Date:  1999-01-01       Impact factor: 2.778

2.  Hypersensitivity skin rash: an adverse drug reaction to clopidogrel loading dose.

Authors:  Ramesh M Gowda; Deepika Misra; Ijaz A Khan
Journal:  Int J Cardiol       Date:  2004-06       Impact factor: 4.164

3.  Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Carlo Patrono; Barry Coller; Garret A FitzGerald; Jack Hirsh; Gerald Roth
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

4.  Clopidogrel desensitization.

Authors:  Mary Lee-Wong; Deval Gadhvi; David Resnick
Journal:  Ann Allergy Asthma Immunol       Date:  2006-05       Impact factor: 6.347

5.  Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy.

Authors:  Eugène P McFadden; Eugenio Stabile; Evelyn Regar; Edouard Cheneau; Andrew T L Ong; Timothy Kinnaird; William O Suddath; Neil J Weissman; Rebecca Torguson; Kenneth M Kent; August D Pichard; Lowell F Satler; Ron Waksman; Patrick W Serruys
Journal:  Lancet       Date:  2004 Oct 23-29       Impact factor: 79.321

6.  Rapid oral desensitisation procedure in clopidogrel hypersensitivity.

Authors:  B Oppedijk; D A M Odekerken; J J van der Wildt; C F Melissant
Journal:  Neth Heart J       Date:  2008       Impact factor: 2.380

7.  Clopidogrel hypersensitivity syndrome with rash, fever, and neutropenia.

Authors:  Matthew P Doogue; Evan J Begg; Paul Bridgman
Journal:  Mayo Clin Proc       Date:  2005-10       Impact factor: 7.616

8.  Clopidogrel (Plavix) desensitization: a case series.

Authors:  Miguel G Camara; Francis Q Almeda
Journal:  Catheter Cardiovasc Interv       Date:  2005-08       Impact factor: 2.692

9.  Antiplatelet therapy in patients undergoing coronary stenting: The risk of late stent thrombosis.

Authors:  J M Ten Berg; J W van Werkum; A A C M Heestermans; W Jaarsma; R M A Hautvast; P den Heijer; M J de Boer
Journal:  Neth Heart J       Date:  2006-09       Impact factor: 2.380

10.  [Thrombosis of a coronary stent after discontinuing treatment with clopidogrel].

Authors:  J W van Werkum; A A C M Heestermans; W Jaarsma; R W M Hautvast; M J de Boer; J M ten Berg
Journal:  Ned Tijdschr Geneeskd       Date:  2006-04-15
View more
  2 in total

1.  Rapid oral desensitisation procedure in clopidogrel hypersensitivity.

Authors:  B Oppedijk; D A M Odekerken; J J van der Wildt; C F Melissant
Journal:  Neth Heart J       Date:  2008       Impact factor: 2.380

Review 2.  Management Strategies for Clopidogrel Hypersensitivity.

Authors:  Craig J Beavers; Nicolas W Carris; Kathryn M Ruf
Journal:  Drugs       Date:  2015-06       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.